OUR VISION IS TO REDUCE ILLNESS AND DEATH ASSOCIATED WITH FUNGAL DISEASES WORLDWIDE.

News

Keep up to date with the latest news items from GAFFI.

Access to Medicines Foundation

Posted .

About 2 billion people have no access to modern medicines, according to the Access to Medicines Foundation’s Founder and CEO Wim Leereveld. In a perspective piece in the New England Journal of Medicine, Hans Hogerzeil of Groningen, also in the Netherlands, reviews the 2012 index rankings of the major global pharmaceutical companies in terms of… Read more »

Read more >

Mycetoma is added to the WHO list of neglected tropical diseases

Posted .

Mycetoma is a chronic, progressively destructive morbid inflammatory disease usually of the foot but any part of the body can be affected. Infection is most probably acquired by traumatic inoculation of certain fungi and  ‎bacteria into the subcutaneous tissue. Mycetoma was described in the modern literature in 1694 but was first reported in the mid-19th… Read more »

Read more >

Assessment of birth defects when taking fluconazole or itraconazole

Posted .

In a study of nearly a million Danish pregnant women of whom 7352 were exposed to fluconazole and 687 to itraconazole in the first trimester, Ditte Molgaard-Nielsen and colleagues from the Serums Staten Institute in Copenhagen found a 3-fold increase in the heart defect tetralogy of Fallot and a 2-fold increase in hypoplastic left heart… Read more »

Read more >

Berwick report on patient safety in the NHS (UK)

Posted .

Following the Francis report into the breakdown of care in the NHS system in Mid Staffordshire hospitals, David Cameron requested Don Berwick a renowned international patient safety expert to form an advisory group, to guide the changes required within the NHS to ensure patient safety. The Berwick report describes some of those problems (view report). Among… Read more »

Read more >

Ketoconazole withdrawn by FDA, for almost all indications

Posted .

Ketoconazole, the world’s first oral azole antifungal, is being retired by the FDA. First launched by Janssen Pharmaceutica (Belgium) in 1985, it transformed the treatment of oral and oesophageal candidiasis and some endemic mycoses such as coccidioidomycosis. This week, the FDA restricted its use to the occasional patient with endemic mycoses, as a last resort…. Read more »

Read more >

Nearly 5 million Asthmatics have ABPA and could benefit from Antifungal Therapy

Posted .

Researchers in Toronto and Manchester estimate that 4,837,000 adults with asthma have allergic bronchoplulmonary aspergillosis or ABPA, which usually improves substantially with antifungal treatment. Their work, published today in the journal Medical Mycology, has re-estimated the total number of asthmatics worldwide – a remarkable 193 million, of whom 24 million live in the USA, 20… Read more »

Read more >

Better Treatment For Cryptococcal Meningitis With Flucytosine In Combination With Amphotericin B

Posted .

A three-way randomised study (1) of cryptococcal meningitis in Vietnam has convincingly shown the benefit of flucytosine with amphotericin B. Jeremy Day and 22 colleagues in Ho Chi Minh City at the Oxford University Clinical Research Unit studied 299 patients, all with AIDS and cryptococcal meningitis and found that the 100 patients who received amphotericin B (1… Read more »

Read more >

Access To Diagnosis And Treatment For Cryptococcal Meningitis

Posted .

Better outcomes for AIDS patients with cryptococcal meningitis are in prospect following a crucial sharing and planning meeting in Geneva, March 18-19 2013. At the instigation of the US Centres for Disease Control, attendees from LIFE, WHO, Medicines Sans Frontieres (MSF), Clinton Health Access and numerous universities and public health institutions, the key barriers to access to… Read more »

Read more >

Ecdc Issues Risk Assessment On Azole Resistance In Aspergillus From Environmental Azole Fungicide.

Posted .

Today the European Centre for Disease Prevention and Control (ECDC) issued a risk assessment report on azole resistance in Aspergillus spp. and its possible link to environmental usage of azole fungicides. An increase of strains of Aspergillus causing serious human infection showing resistance to azole antifungals has been detected in several European countries although the number of studies is… Read more »

Read more >